Meeting
2023 ASCO Annual Meeting
Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer.
Authors
Robert L. Coleman
US Oncology Research/Sarah Cannon Research Institute and GOG-Foundation, The Woodlands, TX
Robert L. Coleman , Jessica Perhanidis , Linda Kalilani , Nicole M. Zimmerman , Amanda Golembesky , Kathleen N. Moore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5592)
DOI
10.1200/JCO.2023.41.16_suppl.5592
Abstract #
5592
Poster Bd #
287
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.
First Author: Mansoor Raza Mirza
Poster
2019 ASCO Annual Meeting
Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence.
First Author: Melinda Louie-Gao
Poster
2017 ASCO Annual Meeting
Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.
First Author: Mansoor Raza Mirza
Poster
2017 ASCO Annual Meeting
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
First Author: Ursula A. Matulonis